Live Case will be Broadcasted Today at 11:00am ET TEL AVIV, Israel, Jan. 18, 2022 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery Disease […]
Tag: CGUARD EPS
InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS
TEL AVIV, Israel, July 23, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces the initiation of enrollment […]
InspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China
New Chinese Distributor Will Also Invest in At-The-Market Private Placement TEL AVIV, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by […]
InspireMD Gains Registration Clearance of its CGuard™ Embolic Prevention System (EPS) in Brazil
TEL AVIV, Israel, July 23, 2020 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced it has obtained registration […]
InspireMD Reports Updated Positive CGuard™ EPS Data Presented at VEITH 2019
CGuard™ EPS clinical data featured as a prominent discussion point in multiple key presentations Data from investigator-initiated multicenter, 729-patient IRONGUARD 2 study suggests that the use of CGuard™ EPS in routine clinical practice is associated with no major periprocedural, 30-day […]
InspireMD Provides Business Update
TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today provided a business update. Positive CGuard™ […]
InspireMD Reports 94% Increase in CGuard™ EPS Revenues for the Second Quarter of 2018
TEL AVIV, Israel, Aug. 06, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the second […]
InspireMD Announces Opening of First Two CGuard™ EPS Centers of Excellence
Tel Aviv, Israel, July 23, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE AMER: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it has […]